SecBot SecBot
8-K ·Filed Jul 30, 2026

PHAT

Phathom Pharmaceuticals, Inc.
MIXED
Impact 5/10
Horizondays Processed3mo ago SEC0001193125-26-324865
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The strong Q2 beat and profitability milestone are positive, but the guidance cut signals caution on H2 trajectory. Monitor the earnings call for details on revenue drivers and the new Phase 3 NERD trial. The stock may trade in a tight range until the next quarter's confirmation.

DirectionMixed
Confidencemedium
Horizondays

Price Chart

Loading chart...

Executive Summary

Phathom Pharmaceuticals reported Q2 2026 net revenue of $74.3M (up 88% YoY, beating consensus of $72.7M) and non-GAAP adjusted EPS of $0.00 (beating consensus of -$0.10 by 100%), marking the first quarter of operating profitability excluding stock-based compensation. However, the company lowered its full-year 2026 revenue guidance to $310-325M from $320-345M, tempering the strong quarterly beat with a more cautious outlook.

Key Financial Metrics

EPS
$0.00
est −$0.10 · +100.0%
Revenue
$74.3M
est $72.7M · +2.2% · +88.0% YoY
Rating
beat
Guidance
$310M-$325M
lowered
Gross Margin
79.7%

Key Facts

  • Q2 2026 net revenue record $74.3M, +88% YoY and +27% QoQ
  • Non-GAAP adjusted net loss just $0.13M, essentially breakeven ($0.00 per share)
  • GAAP net loss narrowed to $17.6M from $75.8M in Q2 2025
  • FY2026 revenue guidance lowered to $310-325M from $320-345M
  • Operating expenses down 33% YoY to $63.1M; cash grew to $182.5M
  • Phase 3 as-needed NERD trial to start Q4 2026; EoE Phase 2 topline Q4 2026

Financial Impact

Q2 revenue beat by 2.2% ($1.6M above consensus); non-GAAP EPS beat by 100% ($0.10 per share); FY guidance cut by ~4.5% at midpoint

revenueepsguidance

Risk Factors

  • Lowered FY2026 guidance could indicate slowing prescription growth or payer pressure
  • Dependence on VOQUEZNA for nearly all revenue; competition from PPIs and generic erosion
  • Phase 2 EoE results and Phase 3 NERD trial execution risk
  • High debt load ($671M total liabilities vs $182M cash) and negative stockholders' equity

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (17 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-324865
Document: d114879d8k.htm0001193125-26-324865
Document: 0001193125-26-324865-index-headers.html0001193125-26-324865
Document: 0001193125-26-324865-index.html0001193125-26-324865
Document: 0001193125-26-324865.txt0001193125-26-324865
8-K Data (Synthetic)0001193125-26-324865

Track record

16 reports on PHAT

Performance horizon

3 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +36.43% at T+60 after the Jul 30, 2026 report. 3 of 5 went positive at some point.

Filters
  1. Nov 10, 20266d ago SC 13G/A Neutral 2/10 Entry $6.28 Now $5.88 −6.37% settles Nov 18
  2. Nov 2, 202614d ago SC 13D/A Neutral 3/10 Entry $5.74 to $5.45 Now $5.88 +2.44% ▼ −5.14% −4.55% vs SPY
  3. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  4. Oct 29, 202618d ago Press Release Bullish 5/10 Entry $6.22 to $5.08 Now $5.88 −5.47% ▼ −18.33% −13.60% vs SPY
  5. Oct 26, 202621d ago 8-K Bearish 5/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
  6. Oct 23, 202624d ago 8-K Bearish 6/10 Entry $5.94 to $5.74 Now $5.88 +1.01% ▲ +3.37% +2.11% vs SPY
  7. Oct 19, 202628d ago Press Release Neutral 1/10 Entry $7.01 Now $5.88 −16.12% No price data
  8. Sep 29, 20266w ago 8-K Neutral 4/10 Entry $7.30 to $6.81 Now $5.88 −19.45% ▼ −6.71% −8.63% vs SPY
  9. Jul 30, 202615w ago 8-K Mixed 5/10 Viewing No price data
  10. Jul 30, 202615w ago Press Release Bearish 6/10 Entry $9.03 to $8.39 Now $5.88 +34.88% ▲ +7.09% +10.71% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026